Trials / Unknown
UnknownNCT00684970
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Tiltan Pharma Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Hamsa-1™ comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety.The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase IIb clinical trial aims to evaluate the efficacy of Hamsa-1™ for the treatment of metastatic Castration Resistant Prostate Cancer (CRPC) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hamsa-1™ TL-118 | Once daily Hamsa-1™ TL-118 |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2014-02-01
- First posted
- 2008-05-28
- Last updated
- 2013-12-05
Locations
5 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT00684970. Inclusion in this directory is not an endorsement.